Compare CRDF & CIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | CIX |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7M | 289.5M |
| IPO Year | 2012 | 1997 |
| Metric | CRDF | CIX |
|---|---|---|
| Price | $1.90 | $23.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.63 | N/A |
| AVG Volume (30 Days) | ★ 659.7K | 1.8K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | ★ 9.45% |
| EPS Growth | ★ 27.37 | 17.04 |
| EPS | N/A | ★ 1.58 |
| Revenue | $365,993.00 | ★ $158,285,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.10 |
| Revenue Growth | ★ 49.61 | 8.46 |
| 52 Week Low | $1.48 | $17.89 |
| 52 Week High | $4.56 | $32.30 |
| Indicator | CRDF | CIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 43.24 |
| Support Level | $1.89 | $22.97 |
| Resistance Level | $2.05 | $23.25 |
| Average True Range (ATR) | 0.13 | 0.50 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 34.69 | 0.00 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.